Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427598 | 1.00 | CNR2 (0.51) | CNR2ALDH1A1RAB9ACYP2C19CYP3A4 | |
| SCHEMBL2485602 | 0.94 | ALDH1A1 (0.50) | ALDH1A1RAB9ACYP2C19CYP3A4CYP2D6 | |
| SCHEMBL16664378 | 0.94 | ALDH1A1 (0.50) | ALDH1A1RAB9ACYP2C19CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2484892 | 0.92 | ALDH1A1 (0.49) | ALDH1A1RAB9ACYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1696017 | 0.88 | MEN1 (0.59) | CNR2KMT2AMEN1MEP1BCYP1A2 | |
| SCHEMBL27827175 | 0.88 | MEN1 (0.59) | CNR2KMT2AMEN1MEP1BCYP1A2 | |
| SCHEMBL19248981 | 0.88 | MEN1 (0.59) | CNR2KMT2AMEN1MEP1BCYP1A2 | |
| SCHEMBL5223607 | 0.86 | CNR2 (0.48) | CNR2ALDH1A1RAB9ACYP2C19CYP3A4 | |
| SCHEMBL5223574 | 0.85 | MEN1 (0.70) | CNR2ALDH1A1RAB9ACYP2C19CYP3A4 | |
| SCHEMBL29228705 | 0.84 | ATM (0.52) | CNR2CYP2C19CYP2D6CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432953-B1 | — | — | None | — | — | US | disclosed |
| CN-118026886-A | Synthesis method of various functionalized beta-amino acid esters | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | disclosed |
| WO-2009001203-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-12-31 | — | — | WO | disclosed |
| EP-0994867-B1 | POLYMORPHIC FORM OF THE TACHYKININ RECEPTOR ANTAGONIST 2-(R)-(1-(R) -(3,5-BIS(TRIFLUOROMETHYL) PHENYL)ETHOXY)-3-(S)-(4-FLUORO) PHENYL-4-(3-5 (-OXO-1H,4H-1,2,4,-TRIAZOLO) METHYLMORPHOLINE | MERCK & CO INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-6638930-B2 | Antiinflammatory agents, analgesics, antiasthmatics, antiemitics and calcium channel blockers for angina, hypertension or ischemia | MERCK & CO. INC. | 2003-10-28 | — | — | US | disclosed |
| US-6583142-B2 | 2-(R)-(1-(R)-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H -1,2,4-triazolo) methyl morpholine; antagonizing effect of substance P at its receptor site, blockade of neurokinin-1 receptors | MERCK & CO. | 2003-06-24 | — | — | US | disclosed |
| US-20030027825-A1 | Polymorphic form of a tachykinin receptor antagonist | MERCK & CO. INC. | 2003-02-06 | — | — | US | disclosed |
| US-6432953-B2 | 2-(R)-(1-(R)-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL)ETHOXY)-3-(S)-(4 -FLUORO) PHENYL-4-(3-(5-OXO-1H,4H-1,2,4-TRIAZOLO)METHYLMORPHOLINE; TREATING NEUROPATHY, EMESIS, NERVOUS SYSTEM DISORDERS; THERMODYNAMIC STABILITY FOR DRUGS | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | disclosed |
| US-20010041702-A1 | Polymorphic form of a tachykinin receptor antagonist | MERCK & CO., INC. | 2001-11-15 | — | — | US | disclosed |
| EP-0994867-A1 | POLYMORPHIC FORM OF THE TACHYKININ RECEPTOR ANTAGONIST 2-(R)-(1-(R) -(3,5-BIS(TRIFLUOROMETHYL) PHENYL)ETHOXY)-3-(S)-(4-FLUORO) PHENYL-4-(3-5 (-OXO-1H,4H-1,2,4,-TRIAZOLO) METHYLMORPHOLINE | Merck & Co., Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6048859-A | ANTIEMETIC AGENT | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0935599-A1 | 2-METHOXYPHENYLPIPERAZINE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1999-08-18 | — | — | EP | disclosed |
| US-5922706-A | TREATING INFLAMMATORY DISEASES, PAIN OR MIGRAINE, ASTHMA AND EMESIS, AND CALCIUM CHANNEL BLOCKERS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS SUCH AS ANGINA, HYPERTENSION OR ISCHEMIA | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5872116-A | TREATMENT OF INFLAMATION, PAIN, MIGRAINE, ASTHMA AND EMESIS | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1999001444-A1 | POLYMORPHIC FORM OF THE TACHYKININ RECEPTOR ANTAGONIST 2-(R)-(1-(R) -(3,5-BIS(TRIFLUOROMETHYL) PHENYL)ETHOXY)-3-(S)-(4-FLUORO) PHENYL-4-(3-5 (-OXO-1H,4H-1,2,4,-TRIAZOLO) METHYLMORPHOLINE | MERCK & CO., INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5780467-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES, PAIN OR MIGRAINE, ASTHMA AND EMESIS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998018797-A1 | 2-METHOXYPHENYLPIPERAZINE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-05-07 | — | — | WO | disclosed |
| US-5719147-A | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5691336-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; THERAPY OF ASTHMA, EMESIS | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | TRPM7, TRPM2, TRPM5 | CNR2 81/4885ALDH1A1 3320/4885RAB9A 3791/4885 |
| US-20010041702-A1 | Polymorphic form of a tachykinin receptor antagonist | OPRL1, MC3R, OPRK1 | CNR2 119/4885ALDH1A1 3984/4885RAB9A 3466/4885 |
| US-20030027825-A1 | Polymorphic form of a tachykinin receptor antagonist | OPRL1, MC3R, MC5R | CNR2 118/4885ALDH1A1 4047/4885RAB9A 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.